Huntington’s hurt continues
Annexon becomes the latest group to provide a confusing update in the disease.
Markets punish Uniqure for Huntington’s vagueness
Lack of clarity on safety and efficacy causes shareholders to decamp.
Neurocrine provides some good news in Huntington’s
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
